Other Information .
−Removed: Incorporated By Reference
−Removed: Master Services Agreement, dated September 9, 2022, by and between Factor Bioscience Inc.
−Removed: and the Company.
−Removed: Exhibit 10.1 to Form 8-K filed on September 15, 2022
−Removed: Separation Agreement and General Release, dated August 24, 2022, by and between the Company and Kevin D’Amour.
−Removed: Exhibit 10.1 to Form 8-K/A filed on September 1, 2022
−Removed: Third Amended and Restated Exclusive License Agreement, dated November 1, 2020, by and between Factor Bioscience Limited and Novellus
−Removed: Therapeutics Limited.
−Removed: Filed herewith
+Added: Incorporated By
+Added: Exclusive License Agreement, dated February 20, 2023, by and between Factor Bioscience Limited and Eterna Therapeutics Inc.
+Added: Exhibit 10.1 to Form 8-K filed on February 22, 2023
+Added: Purchase Agreement, dated as of April 5, 2023, by and between Eterna Therapeutics Inc.
+Added: and Lincoln Park Capital Fund, LLC
+Added: Exhibit 10.1 to Form 8-K filed on April 11, 2023
+Added: Registration Rights Agreement, dated as of April 5, 2023, by and between Eterna Therapeutics Inc.
+Added: and Lincoln Park Capital Fund, LLC
+Added: Exhibit 10.1 to Form 8-K filed on April 11, 2023
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
19 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
−Removed: * Management contract or compensation plan or arrangement
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ETERNA THERAPEUTICS INC.
−Removed: November 14, 2022
−Removed: /s/ Andrew Jackson
−Removed: Andrew Jackson
−Removed: Chief Financial Officer
−Removed: (on behalf of the Registrant and as Principal Financial Officer)
+Added: /s/ Matthew Angel
+Added: Matthew Angel
+Added: Chief Executive Officer and President
+Added: (on behalf of the Registrant and as Principal Executive Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.